KR100694011B1 - 다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법 - Google Patents

다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법 Download PDF

Info

Publication number
KR100694011B1
KR100694011B1 KR1020017009163A KR20017009163A KR100694011B1 KR 100694011 B1 KR100694011 B1 KR 100694011B1 KR 1020017009163 A KR1020017009163 A KR 1020017009163A KR 20017009163 A KR20017009163 A KR 20017009163A KR 100694011 B1 KR100694011 B1 KR 100694011B1
Authority
KR
South Korea
Prior art keywords
cpn10
ifn
chaperonin
beta
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009163A
Other languages
English (en)
Korean (ko)
Other versions
KR20020002376A (ko
Inventor
모튼할
카바나그앨리스
Original Assignee
더 유니버서티 어브 퀸슬랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버서티 어브 퀸슬랜드 filed Critical 더 유니버서티 어브 퀸슬랜드
Publication of KR20020002376A publication Critical patent/KR20020002376A/ko
Application granted granted Critical
Publication of KR100694011B1 publication Critical patent/KR100694011B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020017009163A 1999-01-20 2000-01-20 다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법 Expired - Fee Related KR100694011B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8239 1999-01-20
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment

Publications (2)

Publication Number Publication Date
KR20020002376A KR20020002376A (ko) 2002-01-09
KR100694011B1 true KR100694011B1 (ko) 2007-03-12

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009163A Expired - Fee Related KR100694011B1 (ko) 1999-01-20 2000-01-20 다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법

Country Status (12)

Country Link
US (1) US20090214473A1 (https=)
EP (1) EP1150703B1 (https=)
JP (1) JP4691257B2 (https=)
KR (1) KR100694011B1 (https=)
AT (1) ATE313332T1 (https=)
AU (2) AUPP823999A0 (https=)
CA (1) CA2361081C (https=)
DE (1) DE60024967T2 (https=)
DK (1) DK1150703T3 (https=)
ES (1) ES2255484T3 (https=)
PT (1) PT1150703E (https=)
WO (1) WO2000043033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2457930A1 (en) 2005-08-31 2012-05-30 CBIO Limited Modified chaperonin 10
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015339A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Antagonists to chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
KR20020002376A (ko) 2002-01-09
ATE313332T1 (de) 2006-01-15
AU2527100A (en) 2000-08-07
ES2255484T3 (es) 2006-07-01
CA2361081C (en) 2010-09-21
JP4691257B2 (ja) 2011-06-01
EP1150703B1 (en) 2005-12-21
EP1150703A1 (en) 2001-11-07
JP2002535286A (ja) 2002-10-22
CA2361081A1 (en) 2000-07-27
DE60024967D1 (en) 2006-01-26
PT1150703E (pt) 2006-05-31
WO2000043033A1 (en) 2000-07-27
DK1150703T3 (da) 2006-05-29
EP1150703A4 (en) 2004-11-10
DE60024967T2 (de) 2006-08-17
US20090214473A1 (en) 2009-08-27
AU771867B2 (en) 2004-04-01
AUPP823999A0 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
Zhou et al. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes
DE69332518T2 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
Borron et al. Surfactant associated protein-A inhibits human lymphocyte proliferation and IL-2 production.
EP0979099B1 (en) Use of lactoferin in the treatment of allergen induced disorders
US20090214473A1 (en) Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
Takagi et al. Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice
US5624938A (en) Use of chloroquine to treat multiple sclerosis
KR20000070460A (ko) 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
EP1369119A1 (en) Il-12 expression controlling agents
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
EP1082131A2 (en) Immunoregulator
US20110294736A1 (en) Compounds and methods for the treatment of autoimmune and inflammatory disease
Di Rosa et al. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis
US8796225B2 (en) Regulation of immune responses by modulation of the function of antigen presenting cells
US5317012A (en) Human growth hormone induced improvement in depressed T4/T8 ratio
KR101324647B1 (ko) 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
US20010006682A1 (en) Method for treating patients with suppressed immune systems
EP1501505B1 (en) Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases
JP2020505050A (ja) 免疫寛容性プラズマサイトイド樹状細胞及びその製造方法
AU2003273758A1 (en) Treatment of allergic conditions by use of il 21
EP1731163A2 (en) Treatment of allergic conditions by use of IL 21
JPS6354327A (ja) 治療用組成物
AU2013205017B2 (en) Regulation of immune responses by modulation of the function of antigen presenting cells
WO1998035696A1 (en) Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
WO1994023739A1 (en) METHOD OF DECREASING THE TOXICITY OF THERAPEUTIC COMPOSITIONS USING THYMOSIN β¿4?

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20120222

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130307

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130307

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000